Company intelligence / Profile preview

INTA Systems

Pisa, Tuscany, Italy

Ownership: Private
Development stage: Preclinical

Overview

The company’s NanoAnalyzer platform has demonstrated the ability to rapidly detect up to six TBI biomarkers from a single drop of blood. Results are available within minutes and accessible via cloud database. The device aims to provide cost-effective point-of-care diagnostics with accuracy comparable to laboratory methods or CT scans. Full clinical results pending; commercial launch targeted for research use in 2025[1][2].

Therapeutic areas: OtherNeurology
Modalities: Biosensors (lab-on-chip)ImmunosensingNanoacoustics-based detection; not focused on therapeutics like small molecules or mAbs but rather diagnostic modalities[1][2].
Industry: Protein Biomarker Diagnostics

Partnerships

Academic partnerships with Scuola Normale Superiore and CNR-NANO as founding institutions/spin-off originators[2]

Beyond the preview

Go deeper on INTA Systems.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on INTA Systems.

Explore the full profile